These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 7788423)

  • 1. The prognostic value of plasma viremia in HIV-infected patients under AZT treatment: a two-year follow-up study.
    Ruffault A; Michelet C; Jacquelinet C; Guist'hau O; Genetet N; Bariou C; Colimon R; Cartier F
    J Acquir Immune Defic Syndr Hum Retrovirol; 1995 Jul; 9(3):243-8. PubMed ID: 7788423
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Soluble tumor necrosis factor receptors as surrogate markers for the assessment of zidovudine treatment in asymptomatic HIV-1 infection.
    Godfried MH; van der Poll T; Mulder JW; Weverling GJ; Endert E; Lange JM; Sauerwein HP
    J Acquir Immune Defic Syndr Hum Retrovirol; 1995 Dec; 10(5):531-9. PubMed ID: 8548332
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Viraemia and p24 antigenaemia are independent risk factors for the emergency of a zidovudine-resistant genotype in nucleoside analogue-treated HIV-1 infection.
    Relimpio F; Rey C; Pineda JA; Leal M; Caruz A; Sánchez-Quijano A; Lissen E
    Antivir Ther; 1997 Apr; 2(2):99-104. PubMed ID: 11322281
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevalence of viremia in human immunodeficiency virus-infected patients with renal disease.
    Kimmel PL; VedBrat SS; Pierce PF; Umana WO; Shepherd L; Verme DA; Hirsch RP; Hellman KB
    Arch Intern Med; 1995 Aug 7-21; 155(15):1578-84. PubMed ID: 7618979
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Quantitative viremia and p24 antigenemia in short-term follow-up of the treatment with zidovudine in twenty HIV infected patients].
    Tamalet C; Puel J; Fleury H; Ferchal F; Agut H; Brun-Vezinet F; Botti G; Rouzioux C
    Pathol Biol (Paris); 1993 Apr; 41(4):399-403. PubMed ID: 8233642
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of drug resistance genotypes on CD4+ counts and plasma viremia in heavily antiretroviral-experienced HIV-infected patients.
    Rodes B; García F; Gutierrez C; Martinez-Picado J; Aguilera A; Saumoy M; Vallejo A; Domingo P; Dalmau D; Ribas MA; Blanco JL; Pedreira J; Perez-Elias MJ; Leal M; de Mendoza C; Soriano V;
    J Med Virol; 2005 Sep; 77(1):23-8. PubMed ID: 16032728
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Early and prolonged decrease of viremia in HIV-1-infected patients treated with didanosine.
    Yerly S; Kaiser L; Baumberger C; Hirschel B; Perrin LH
    J Acquir Immune Defic Syndr Hum Retrovirol; 1995 Apr; 8(4):358-64. PubMed ID: 7882100
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
    Van Vaerenbergh K
    Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Plasma HIV-1 RNA as a predictor of the efficacy of adding zalcitabine to a previous regimen with zidovudine.
    Ruiz L; Romeu J; Ibáñez A; Cabrera C; Puig T; Morales MA; Sirera G; Clotet B
    Antivir Ther; 1996 Dec; 1(4):220-4. PubMed ID: 11324824
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Zidovudine and lamivudine: results of phase III studies.
    Staszewski S
    J Acquir Immune Defic Syndr Hum Retrovirol; 1995; 10 Suppl 1():S57. PubMed ID: 8595510
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term outcome and treatment modifications in a prospective cohort of human immunodeficiency virus type 1-infected patients on triple-drug antiretroviral regimens. Triest Cohort Investigators.
    Girard PM; Guiguet M; Bollens D; Goderel I; Meyohas MC; Lecomte I; Raguin G; Frottier J; Rozenbaum W; Jaillon P
    Clin Infect Dis; 2000 Oct; 31(4):987-94. PubMed ID: 11049781
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Viral load, viral phenotype modification, zidovudine susceptibility and reverse transcriptase mutations during the first 6 months of zidovudine monotherapy in HIV-1-infected people.
    Rusconi S; De Pasquale MP; Mainini F; Bulgheroni E; Kurtagic S; Gori A; Violin M; Zanchetta N; Moroni M; Balotta C; Galli M
    Antivir Ther; 1996 Dec; 1(4):211-9. PubMed ID: 11324823
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An observational study on patients treated or not for acute HIV infection.
    Mussini C; Cozzi-Lepri A; Bedini A; Borghi V; Mongiardo N; Cossarizza A; Esposito R
    J Biol Regul Homeost Agents; 2002; 16(1):79-82. PubMed ID: 12003180
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Open trial of tacrine therapy in 70 HIV-infected patients.
    Fredj G; Dietlin F; Jasmin C; Maurisson G; Barbier M; Bayce P; Ratiney R; Rudant E; Debat P; Kalifa D
    Int J Clin Pharmacol Ther Toxicol; 1992 Sep; 30(9):313-6. PubMed ID: 1358832
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Residual viraemia in HIV-1-infected patients with plasma viral load Ostrowski SR; Katzenstein TL; Pedersen BK; Gerstoft J; Ullum H
    Scand J Immunol; 2008 Dec; 68(6):652-60. PubMed ID: 19055701
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Acute decrease in HIV-1 viral load after initiation of zidovudine therapy: implications for interrupting vertical transmission.
    Jackson JB
    Pediatr AIDS HIV Infect; 1995 Dec; 6(6):358-9. PubMed ID: 11361462
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic value of proliferative responses to HIV-1 antigen in chronically HIV-infected patients under antiretroviral therapy.
    Mohm JM; Rump JA; Schulte-Mönting J; Schneider J
    J Clin Virol; 2004 Jul; 30(3):239-42. PubMed ID: 15135742
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The prognostic markers of survival and progression in HIV-1 infection. A study of CD4+ lymphocytes, antigen p24 and viral load during 3 years in a cohort of 251 patients].
    Rubio Caballero M; Nogués Biau A; Falguera Sacrest M; Puig Ganau T; Lecha N; Rubio Rivas C
    An Med Interna; 2000 Oct; 17(10):533-7. PubMed ID: 11109648
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term suppression of plasma viremia with highly active antiretroviral therapy despite virus evolution and very limited selection of drug-resistant genotypes.
    Pariente N; Pernas M; de la Rosa R; Gómez-Mariano G; Fernández G; Rubio A; López M; Benito JM; López-Galíndez C; Leal M; Domingo E; Martinez MA; Mas A
    J Med Virol; 2004 Jul; 73(3):350-61. PubMed ID: 15170628
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Virological monitoring in subjects with HIV infection under treatment with zidovudine (AZT)].
    Fiore JR; Angarano G; Fico C; Lo Caputo S; Fracasso C; Barile M; Pastore G
    Boll Soc Ital Biol Sper; 1990 Jun; 66(6):601-6. PubMed ID: 2124131
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.